Get the Stockscreener App
25.88
3.11%
-0.83
After Hours:
26.45
0.57
+2.20%
Greenwich Lifesciences Inc stock is traded at $25.88, with a volume of 188.86K.
It is down -3.11% in the last 24 hours and up +3.81% over the past month.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
See More
Previous Close:
$26.71
Open:
$26.15
24h Volume:
188.86K
Relative Volume:
0.35
Market Cap:
$358.56M
Revenue:
-
Net Income/Loss:
$-19.48M
P/E Ratio:
-17.68
EPS:
-1.4641
Net Cash Flow:
$-8.59M
1W Performance:
-2.49%
1M Performance:
+3.81%
6M Performance:
+125.83%
1Y Performance:
+126.03%
1-Day Range:
$24.61
$26.49
1-Week Range:
$24.61
$30.25
52-Week Range:
$7.78
$34.10
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Name
Greenwich Lifesciences Inc
Sector
Industry
Phone
203-434-3290
Address
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Compare GLSI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
25.88 | 370.05M | 0 | -19.48M | -8.59M | -1.4641 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Initiated | Noble Capital Markets | Outperform |
| Sep-01-21 | Initiated | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Stock (GLSI) Latest News
Greenwich LifeSciences Inc initiates new US clinical sites for Flamingo-01 phase III trial - marketscreener.com
Greenwich LifeSciences expands Phase III trial to City of Hope sites - Investing.com
Greenwich LifeSciences, Inc. Announces Addition of City of Hope to Flamingo-01 - marketscreener.com
City of Hope joins breast cancer trial, widening access across US sites - Stock Titan
Liquidity Mapping Around (GLSI) Price Events - Stock Traders Daily
Greenwich LifeSciences to present trial data at AACR meeting By Investing.com - Investing.com Canada
Greenwich LifeSciences to present trial data at AACR meeting - Investing.com
Greenwich Lifesciences provides update on upcoming AACR meeting - marketscreener.com
Greenwich Lifesciences Provides Update On Upcoming Aacr Meeting - TradingView
Greenwich LifeSciences, Inc. Announces Presentation of FLAMINGO-01 Phase III Clinical Trial Data at AACR Meeting 2026 - Quiver Quantitative
Greenwich LifeSciences to share AACR Meeting plans - Traders Union
Greenwich LifeSciences Provides Update on Upcoming AACR Meeting - GlobeNewswire Inc.
Why is GLSI stock rising today? - MSN
Breakthrough in Clinical Trial Data: Biopharmaceutical company Greenwich Lifesciences Inc (NASDAQ: GLSI) recently announced the latest analysis results of its core immunotherapy GP2 in adjuvant treatment for breast cancer. - Bitget
Why Is GLSI Stock Rising Today? - Mena FN
Greenwich LifeSciences reports reduced cancer recurrence in trial - Investing.com
Greenwich LifeSciences provides update showing continued reduction in recurrence rate in the open label arm of Flamingo-01 - marketscreener.com
Greenwich Lifesciences Provides Update Showing Continued Reduction In Recurrence Rate In The Open Label Arm Of Flamingo-01 - TradingView
Greenwich LifeSciences reports reduced cancer recurrence in trial By Investing.com - Investing.com UK
Breast cancer trial sees under 1% yearly recurrences in GLSI-100 arm - Stock Titan
Greenwich LifeSciences begins using commercial GP2 at US sites By Investing.com - Investing.com South Africa
Greenwich LifeSciences begins using commercial GP2 at US sites - Investing.com
Greenwich LifeSciences Provides Update on Phase III Clinical Trial FLAMINGO-01 and Commercial Manufacturing of GP2 - Quiver Quantitative
Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01 - Sahm
Big Money Moves: Is Greenwich LifeSciences Inc undervalued by DCF analysisPortfolio Performance Summary & Free Community Supported Trade Ideas - baoquankhu1.vn
Greenwich LifeSciences (NASDAQ:GLSI) Trading Up 11.6% – Should You Buy? - Defense World
Greenwich LifeSciences (NASDAQ:GLSI) Trading Up 11.6%Should You Buy? - MarketBeat
Why (GLSI) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Why did Greenwich LifeSciences stock soar pre-market today? - MSN
ETF Watch: Is Greenwich LifeSciences Inc a turnaround storyWeekly Investment Recap & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Market Review: Is Greenwich LifeSciences Inc a stock for growth or value investorsMarket Activity Summary & High Conviction Buy Zone Alerts - baoquankhu1.vn
GLSI Should I Buy - Intellectia AI
Noble Financial Sticks to Their Buy Rating for Greenwich LifeSciences (GLSI) - The Globe and Mail
Greenwich LifeSciences reports 33% rise in trial screening rate By Investing.com - Investing.com Canada
Greenwich LifeSciences reports 33% rise in trial screening rate - Investing.com South Africa
Greenwich LifeSciences accelerates patient screening in FLAMINGO-01 clinical trial - Traders Union
Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01 - GlobeNewswire
US Stocks Recap: Is Greenwich LifeSciences Inc undervalued by DCF analysisTrade Exit Summary & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Aug Sentiment: Can Greenwich LifeSciences Inc expand into new marketsOptions Play & Long-Term Safe Investment Ideas - baoquankhu1.vn
GLSI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Understanding Momentum Shifts in (GLSI) - Stock Traders Daily
Greenwich LifeSciences abstracts accepted at AACR 2026 meeting By Investing.com - Investing.com Australia
Greenwich LifeSciences abstracts accepted at AACR 2026 meeting - Investing.com Nigeria
Rally Mode: Is BTCM a cyclical or defensive stockWall Street Watch & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Greenwich lands 2 AACR 2026 slots, first with FLAMINGO-01 Steering Committee - Stock Titan
GLSI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026 - ChartMill
Analysis Recap: Is SPRY stock showing strong momentumQuarterly Market Summary & Risk Controlled Swing Alerts - baoquankhu1.vn
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Short Interest Down 14.7% in January - MarketBeat
How interest rate cuts could boost Greenwich LifeSciences Inc. stockJuly 2025 Macro Moves & Consistent Return Investment Signals - mfd.ru
GLSI PE Ratio & Valuation, Is GLSI Overvalued - Intellectia AI
Greenwich Lifesciences Inc Stock (GLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.20%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):